About Us
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine.
Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives.
Vision
To create a healthier world for all people.
Mission
To discover, develop and deliver innovative therapeutics for people with life-threatening diseases.
Core Values
Integrity
Doing What’s Right
Inclusion
Encouraging Diversity
Teamwork
Working Together
Accountability
Taking Personal Responsibility
Excellence
Being Your Best
Learn how Gilead employees help bring our vision, mission and core values to life
Our History
In the ancient world, there was a tree that was known for its healing powers. Like the medicinal resin it produced, the tree was called the Balm of Gilead.
Centuries later, the need for healing continued to grow. We were founded in 1987 to bring new hope in the face of devastating diseases. For more than 35 years, we’ve been at the forefront of some of the world’s greatest public health challenges.
We delivered a cure for hepatitis C. We’ve helped transform the treatment and prevention of HIV. We’ve taken on cancer and COVID-19. And we continue to set our sights on preventing, treating and curing life-threatening diseases through the next generation of life-changing medicines and global health partnerships.
Learn more about our impact across our therapeutic areas of focus
What's Next
In recent years, we’ve been evolving the company and our strategy to deliver more benefits to more patients. We’re well on our way to achieving our goals this decade and beyond, as we continue to pursue bold ambitions across multiple therapeutic areas.
We’re playing a key role in ending the HIV epidemic for everyone, everywhere. We’re working to eliminate hepatitis C as a public health problem by 2030. In oncology, we’re on track to deliver transformative therapies in more than 20+ indications, impact more than 500,000 patient lives and be a top 10 oncology company by 2030. And we’re growing our inflammation portfolio with new approaches to control chronic inflammation and fibrosis.
Our Strategic Ambitions
